Please use this identifier to cite or link to this item: http://hdl.handle.net/10397/76685
Title: Chronic inflammation-elicited liver progenitor cell conversion to liver cancer stem cell with clinical significance
Authors: Li, XF
Chen, C
Xiang, DM
Qu, L
Sun, W
Lu, XY
Zhou, TF
Chen, SZ
Ning, BF
Cheng, Z
Xia, MY
Shen, WF
Yang, W
Wen, W
Lee, TKW 
Cong, WM
Wang, HY
Ding, J
Issue Date: 2017
Publisher: Wiley
Source: Hepatology, 2017, p. 2 How to cite?
Journal: Hepatology 
Abstract: The substantial heterogeneity and hierarchical organization in liver cancer support the theory of liver cancer stem cells (LCSCs). However, the relationship between chronic hepatic inflammation and LCSC generation remains obscure. Here, we observed a close correlation between aggravated inflammation and liver progenitor cell (LPC) propagation in the cirrhotic liver of rats exposed to diethylnitrosamine. LPCs isolated from the rat cirrhotic liver initiated subcutaneous liver cancers in nonobese diabetic/severe combined immunodeficient mice, suggesting the malignant transformation of LPCs toward LCSCs. Interestingly, depletion of Kupffer cells in vivo attenuated the LCSC properties of transformed LPCs and suppressed cytokeratin 19/Oval cell 6-positive tumor occurrence. Conversely, LPCs cocultured with macrophages exhibited enhanced LCSC properties. We further demonstrated that macrophage-secreted tumor necrosis factor-α triggered chromosomal instability in LPCs through the deregulation of ubiquitin D and checkpoint kinase 2 and enhanced the self-renewal of LPCs through the tumor necrosis factor receptor 1/Src/signal transducer and activator of transcription 3 pathway, which synergistically contributed to the conversion of LPCs to LCSCs. Clinical investigation revealed that cytokeratin 19/Oval cell 6-positive liver cancer patients displayed a worse prognosis and exhibited superior response to sorafenib treatment. Conclusion: Our results not only clarify the cellular and molecular mechanisms underlying the inflammation-mediated LCSC generation but also provide a molecular classification for the individualized treatment of liver cancer.
URI: http://hdl.handle.net/10397/76685
ISSN: 0270-9139
EISSN: 1527-3350
DOI: 10.1002/hep.29372
Appears in Collections:Journal/Magazine Article

Access
View full-text via PolyU eLinks SFX Query
Show full item record

SCOPUSTM   
Citations

3
Citations as of May 11, 2018

WEB OF SCIENCETM
Citations

2
Last Week
0
Last month
Citations as of May 20, 2018

Page view(s)

61
Citations as of May 21, 2018

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.